Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is advancing its clinical-stage oncology pipeline, particularly with its promising drug BDTX-1535, which has shown an overall response rate (ORR) of 36% in patients with difficult-to-treat non-small cell lung cancer (NSCLC) harboring specific mutations. The improvement in ORR to 42% when excluding patients without on-target resistance mutations highlights the targeted efficacy of this therapy, suggesting significant therapeutic potential against current market options. Additionally, the company's focus on the unmet need in first-line treatment of non-classical EGFR mutations positions it favorably for future growth, especially with data updates anticipated in 2025 that may further validate its approach.

Bears say

Black Diamond Therapeutics Inc faces significant risks that negatively impact its stock outlook, including potential negative efficacy or safety data for its leading pipeline candidate BDTX-1535, as well as the possibility of disappointing results from other pipeline candidates. The company's recent adjustments to near- to mid-term expense assumptions and commercialization timelines, compounded by a forecasted full-year 2025 net loss of $1.32 per share, indicate reduced financial stability. Additionally, there is concern regarding the risk of long-term dilution, which could further diminish shareholder value.

BDTX has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 9 analysts, BDTX has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.